Streetbeat News

Stock Prices

PXD

A significant bullish stance has been taken on Pioneer Natural Resources (NYSE:PXD) by a large investor, as indicated by unusual options activity. The overall sentiment of these big-money traders is split between 60% bullish and 40% bearish. The whales have been targeting a price range from $200.0 to $270.0 for Pioneer Natural Resources over the last 3 months. Mizuho has maintained their Buy rating on Pioneer Natural Resources, with a price target of $301.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 8:46 pm

VALE

A large investor has taken a bullish stance on Vale (NYSE:VALE), with 72% of big-money traders also bullish. The investor's position was noticed through publicly available options history. The options scanner spotted 11 uncommon options trades for Vale, with 4 puts and 7 calls. The whales have been targeting a price range from $3.0 to $20.0 for Vale over the last 3 months. JP Morgan has upgraded its action to Overweight with a price target of $16 and maintained their Overweight rating on Vale with a price target of $18.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 8:46 pm

ASNS

Actelis has achieved Third Party Validation for FIPS cyber protection standard required by government agencies, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:44 pm

CNXC

Concentrix reported worse-than-expected Q3 financial results and issued Q4 adjusted EPS guidance below estimates, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:42 pm

CHN

The China Fund, Inc. (NYSE:CHN) has announced changes to its Discount Management Program, which allows the fund to repurchase up to 10% of its common shares annually. The repurchases are made when shares are trading above a specified discount threshold. The program aims to enhance shareholder value by purchasing Fund shares trading at a discount from their net asset value (NAV) per share. However, there is no guarantee that the program will be effective at reducing any discount in the open market price of Fund shares.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:41 pm

GMDA

Gamida Cell Ltd. (NASDAQ:GMDA) announced that the first patient has received a stem cell transplant with Omisirge, the only allogeneic stem cell therapy approved by the FDA. The company has exceeded its 2023 launch goals, with 15 transplant centers onboarded across the US and confirmed coverage with payers that cover 90% of commercial lives. Gamida Cell is actively engaged with more than 90% of the top 70 transplant centers, which conduct approximately 80% of transplants. The company plans to expand its team from four to eight account managers by the start of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:40 pm

MU

Micron Technology reported its Q4 financial results and issued guidance, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:40 pm

BACK

IMAC Holdings, Inc. (NASDAQ:BACK) has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The company's common stock and warrants will continue to be listed and traded on The Nasdaq Capital Market under the symbols 'BACK' and 'IMACW', respectively.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:39 pm

JEF

Jefferies Financial reported worse-than-expected Q3 financial results, leading to a drop in its share price.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:38 pm

GNSS

Genasys Inc. has announced a proposed public offering of common stock, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:32 pm